REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notice of Full Year Results
15/04/2021 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210415:nRSO5163Va&default-theme=true
RNS Number : 5163V MaxCyte, Inc. 15 April 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Notice of Full Year Results
Gaithersburg, Maryland - 15 April 2021 : MaxCyte (LSE: MXCT, MXCL, MXCN), a
leading provider of cell-engineering platform technologies for next generation
cell-based therapies, will be announcing its financial results for the year
ended 31 December 2020 on Tuesday, 20 April 2021.
Doug Doerfler, Chief Executive Officer, and Amanda Murphy, Chief Financial
Officer, will host a conference call for analysts at 14.00pm BST the day of
the announcement. The presentation will be available on the Investors section
of MaxCyte's website on the day of the meeting at
https://investors.maxcyte.com/news-events/documents-presentations
(https://investors.maxcyte.com/news-events/documents-presentations) .
###
For further information please contact:
MaxCyte Inc. +1 301 944 1660
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
Nominated Adviser and Joint Corporate Broker +44 (0)20 7886 2500
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
Joint Corporate Broker +44 (0)20 7260 1000
Numis Securities Limited
James Black
Duncan Monteith
Joint Corporate Broker +44 (0) 20 7710 7600
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
Financial PR Adviser +44 (0)203 709 5700
Consilium Strategic Communications maxcyte@consilium-comms.com
Mary-Jane Elliott / Chris Welsh
About MaxCyte
MaxCyte is a leading provider of cell-engineering platform technologies that
are driving the next‐generation of cell-based therapies and making a
meaningful difference for patients. The Company's technology is employed by
leading drug developers worldwide, including all of the top ten global
biopharmaceutical companies. MaxCyte has granted 12 strategic platform
licences to leading cell-based therapy developers. Through 2020, MaxCyte has
granted licenses for more than 140 cell therapy programs, with
over 100 licensed for clinical use. MaxCyte was founded in 1998 and is
headquartered in Gaithersburg, Maryland, U.S. For more information,
visit www.maxcyte.com (http://www.maxcyte.com/) .
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END NORUSORRANUSAUR